TRVI
Trevi Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 9 ▲ Trevi Therapeutics announced positive feedback from its End-of-Phase…
- Mar 17 Trevi Therapeutics reported fourth quarter and full-year 2025 financ…
- Apr 17 ▼ Trevi Therapeutics priced a $150.8 million follow-on offering of 11.…
- Apr 17 ▼ Trevi Therapeutics priced a $150 million follow-on offering just one…
- Apr 17 Trevi Therapeutics priced an underwritten public offering of 11,600,…
- Apr 17 Offering: Trevi Therapeutics Announces Pricing of $150 Million Under…
- Apr 20 Offering: Trevi Therapeutics Announces Closing of $173 Million Under…
- Jul 21 BMO Capital initiates
- Sep 15 ▼ 1 insider sell $594.2K at $15.09
- Nov 9 ▲ Earnings: TRVI Q3 2026 Earnings: EPS $-0.13 (+5.4% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $594.2K.
- InstitutionsBULLISH
Q3 2026: 23 added (1 new), 15 trimmed or exited. Largest new: Federated Hermes, $11.1M.
- EstimatesFALLING
Current-quarter EPS estimate −$0.129 → −$0.133 over 90 days. 1 up, 2 down in 30 days.
- Short sellersSTEADY
Short interest +5.3% to 16.86M shares. 10.1 days to cover, ≈11.8% of shares.
- TrendRANGE
5% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Assenagon Asset Management S.A. | DOUBLED | $50.5M |
| Candriam S.C.A. | ADD | $18.8M |
| FRANKLIN TEMPLETON INC | DOUBLED | $14.6M |
| Qube Research & Technologies Ltd | DOUBLED | $12.6M |
| FEDERATED HERMES, INC. | NEW | $11.1M |
| Bank of New York Mellon Corp | DOUBLED | $9.8M |
| CITIGROUP INC | DOUBLED | $7.0M |
| UBS Group AG | ADD | $5.9M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Aug 2026Price is below the lowest target. Median implies +88%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Aug 14, 2026 | Jones Trading MAINTAIN | Buy |
| Aug 7, 2026 | Oppenheimer MAINTAIN | Outperform |
| Aug 7, 2026 | Cantor Fitzgerald MAINTAIN | Overweight |
| Jul 21, 2026 | BMO Capital INITIATE | Outperform |
| Jul 20, 2026 | B. Riley Securities MAINTAIN | Buy |
| Jul 20, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Heffernan Michael Thomas Director Sep 15, 2026 | EXERCISE | $56.0K |
Heffernan Michael Thomas Director Sep 15, 2026 | SELL | $276.5K |
Heffernan Michael Thomas Director Sep 15, 2026 | SELL | $1.6K |
Heffernan Michael Thomas Director Sep 15, 2026 | EXERCISE | $70.1K |
Heffernan Michael Thomas Director Sep 15, 2026 | SELL | $316.2K |
Heffernan Michael Thomas Director Jun 3, 2026 | AWARD | 35,000 sh |
Colangelo Dominick Director Jun 3, 2026 | AWARD | 35,000 sh |
Meeker David P Director Jun 3, 2026 | AWARD | 35,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.13 | -$0.18–-$0.11 | +0.0% | $0.00 |
| Next Q | -$0.16 | -$0.17–-$0.12 | +0.0% | $0.00 |
| Current FY | -$0.50 | -$0.55–-$0.47 | -4.9% | $0.00 |
| Next FY | -$0.60 | -$0.81–-$0.39 | -3.8% | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
7 filings · 5 press releases · 0 bullish · 2 bearish · 2 mixed · 3 neutral- NEUTRAL 8-KNov 9, 2026
Trevi Therapeutics reported a Q3 2026 net loss of $21.5 million, wider than the $11.8 million loss…
Monitor the Phase 2b LAKE trial SSRE analysis expected early Q1 2027 and the initiation of the non-IPF ILD Phase 2 trial in Q1 2027. Topline data from the Phase 3 OCEAN-2 trial is expected in H2…
- NEUTRAL SC 13G/AOct 27, 2026
BlackRock, Inc. filed an amendment to its Schedule 13G for Trevi Therapeutics, Inc., reporting…
Monitor future 13G filings for any change in BlackRock's position; a shift to 13D would signal activist intent. No immediate catalyst from this routine passive update.
- MIXED INST-CLUSTERJun 11, 2026
Four institutional buyers accumulated $90.6M in TRVI during Q4 2025, led by Fidelity ($51.2M add)…
The divergence between active asset managers (AllianceBernstein, Fidelity) adding heavily and Morgan Stanley/BofA exiting suggests a catalyst-driven thesis (likely pipeline data) that not all…
- MIXED INST-CLUSTERJun 11, 2026
A strong institutional cluster for Trevi Therapeutics (TRVI) in Q3 2025 shows 8 buyers adding…
The cluster is dominated by passive/index managers and likely reflects index rebalancing or broad sector rotation into small-cap biotech, not a company-specific catalyst. With Wellington's massive…
All TRVI filing & press-release reports (12)
- 8-K reportNov 9, 2026
- SC 13G/A reportOct 27, 2026
- INST-CLUSTER reportJun 11, 2026
- INST-CLUSTER reportJun 11, 2026
- DEFA14A reportApr 21, 2026
- PRESS-RELEASE reportApr 20, 2026
- 424B5 reportApr 17, 2026
- 8-K reportApr 17, 2026
- PRESS-RELEASE reportApr 16, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 10, 2026
- PRESS-RELEASE reportMar 9, 2026